Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NLM-001

Small molecule · Inhibitor · developed by Nelum

Phase 1/2 Most advanced trial
1 Registered trials

What is NLM-001?

NLM-001 is a Hedgehog pathway inhibitor with immunomodulating and antineoplastic activities. It targets the Hh pathway to disrupt the tumor microenvironment by decreasing cancer-associated fibroblasts and promoting immune cell infiltration, potentially enhancing chemotherapy and immunotherapy efficacy. It is studied in pancreatic ductal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Inhibitor
Pathways
Hedgehog signaling, tumor microenvironment remodeling, immune cell infiltration, Hedgehog pathway
Therapy area
Oncology
Developer
Nelum Corp
In trials of
AGEN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04827953 Phase 1/2 Pancreatic Ductal Adenocarcinoma Active not recruiting AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic Ductal Adenocarcinoma

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.